Perspectives and potential applications of nanomedicine in breast and prostate cancer

Abstract

Nanomedicine is a branch of nanotechnology that includes the development of nanostructures and nanoanalytical systems for various medical applications. Among these applications, utilization of nanotechnology in oncology has captivated the attention of many research endeavors in recent years. The rapid development of nano-oncology raises new possibilities in cancer diagnosis and treatment. It also holds great promise for realization of point-of-care, theranostics, and personalized medicine. In this article, we review advances in nano-oncology, with an emphasis on breast and prostate cancer because these organs are amenable to the translation of nanomedicine from small animals to humans. As new drugs are developed, the incorporation of nanotechnology approaches into medicinal research becomes critical. Diverse aspects of nano-oncology are discussed, including nanocarriers, targeting strategies, nanodevices, as well as nanomedical diagnostics, therapeutics, and safety. The review concludes by identifying some limitations and future perspectives of nano-oncology in breast and prostate cancer management.

Hands-free, wireless goggles for near-infrared fluorescence and real-time image-guided surgery

“…Representative examples of NIR fluorescent dyes include indocyanine green, an FDA-approved NIR dye20, 21, and cypate, a readily functionalized indocyanine green analog 22. We demonstrate that the device can detect fluorescence from as low as 1 nM of indocyanine green dye (Fig.…”

Targeting autophagy using metallic nanoparticles: a promising strategy for cancer treatment

“…Interestingly, nanocarriers can passively accumulate in the leaky vasculature, typical of tumor tissues in a manner known as the enhanced permeability and retention effect (EPR) [100]. Nanocarriers may also be conjugated with specific ligands, to utilize active targeting mechanisms [101]. This allows them to reach specific tissues and release drugs in a stable and controlled manner.…”

Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance

“…The creation of an “industrial culture” of making nanomedicines including their standardized testing and characterization is another challenge. It appears that nanomedicines currently under development will target the most common cancers, such as breast and prostate cancer [55]. The first generation of anti-cancer nanomedicines is based on their “passive” (EPR-mediated) delivery into tumors, and drugs (such as Doxil®) and diagnostic agents (such as SPION (superparamagnetic iron oxide nanoparticles)-based NMR contrast agents) are now approved and in active clinical trials, respectively [56].…”